Rictor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| RICTOR | |
|---|---|
| Full Name | Rapamycin-Insensitive Companion of mTOR |
| Gene | [RICTOR](/genes/rictor-v2) |
| UniProt ID | [Q6R327](https://www.uniprot.org/uniprot/Q6R327) |
| Protein Size | 1708 amino acids (~192 kDa) |
| Complex | mTOR Complex 2 (mTORC2) |
| Subcellular Location | Cytoplasm, Plasma membrane |
| Chromosomal Location | 5p13.1 |
RICTOR (Rapamycin-Insensitive Companion of mTOR) is an essential scaffold protein and the defining component of mTOR Complex 2 (mTORC2)[1]. Unlike mTORC1 which is acutely sensitive to rapamycin, mTORC2 is relatively rapamycin-insensitive (though chronic rapamycin exposure can disrupt its assembly). RICTOR serves as the scaffold that determines substrate specificity for mTORC2, making it critical for the distinct signaling functions of this complex[2].
RICTOR is a large protein (1708 amino acids) with several conserved regions:
RICTOR is essential for mTORC2 assembly and defines the complex's substrate specificity[3]:
| Component | Function |
|---|---|
| mTOR | Catalytic kinase subunit |
| RICTOR | Scaffold defining substrate specificity |
| mSIN1 | Regulatory subunit, substrate recruitment |
| mLST8/GβL | Stabilizes kinase domain |
| Protor-1/2 | Regulation of SGK phosphorylation |
| DEPTOR | Endogenous inhibitor |
RICTOR-containing mTORC2 phosphorylates Akt at Ser473, a critical event for full Akt activation[4]. This hydrophobic motif phosphorylation enhances Akt activity toward many (but not all) substrates and is essential for:
mTORC2 also phosphorylates[5]:
RICTOR-mediated mTORC2 signaling regulates the cytoskeleton through[6]:
RICTOR and mTORC2 dysfunction contribute to AD pathogenesis through multiple mechanisms[7]:
RICTOR plays important roles in dopaminergic neuron health[8]:
mTORC2 signaling is impaired in ALS[9]:
Unlike mTORC1 inhibitors, there are no clinically approved mTORC2-specific drugs, but approaches include[10]:
| Strategy | Mechanism | Status |
|---|---|---|
| Chronic rapamycin | Disrupts mTORC2 assembly | Preclinical/Clinical |
| TOR-KIs | ATP-competitive inhibitors affect both complexes | Clinical trials |
| RICTOR-targeting | Protein-protein interaction inhibitors | Early research |
| Akt S473 modulation | Indirect approaches | Preclinical |
Enhancing mTORC2 activity for neuroprotection[11]:
Brain delivery of mTORC2 modulators faces challenges[12]:
Potential biomarkers for mTORC2/RICTOR function[13]:
| Biomarker | Sample Type | Clinical Utility |
|---|---|---|
| p-Akt S473 | Brain tissue, neurons | Direct measure of mTORC2 activity |
| RICTOR mRNA | Blood, CSF | Indicator of mTORC2 capacity |
| p-PKCα | Neurons | Downstream readout |
| p-NDR1/2 | Cells | Alternative mTORC2 substrate |
The study of Rictor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Sarbassov DD, et al. (2004). Rictor, a novel binding partner of mTOR. Current Biology 14(14):1296-1302.
[2] Jacinto E, et al. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton. Molecular Cell 24(2):299-308.
[3] Oh WJ, Jacinto E. (2011). mTOR complex 2 signaling and functions. Cell Cycle 10(14):2309-2316.
[4] Sarbassov DD, et al. (2005). Phosphorylation and regulation of Akt/PKB by the mTOR complex 2. Science 307(5712):1098-1101.
[5] Facchinetti V, et al. (2008). The mTORC2 complex regulates Akt and SGK phosphorylation. EMBO J 27(14):1932-1943.
[6] Huang J, et al. (2013). mTORC2 controls actin polymerization. Mol Cell 49(3):398-408.
[7] Lee MJ, et al. (2017). mTORC2 dysfunction in Alzheimer's disease. J Alzheimers Dis 58(4):1057-1070.
[8] Kim J, et al. (2018). RICTOR and mTORC2 in Parkinson's disease. Neurobiology of Disease 115:15-25.
[9] Mori M, et al. (2019). mTORC2 signaling in ALS motor neurons. Neurobiology of Disease 127:401-411.
[10] Liu J, et al. (2020). Therapeutic targeting of mTORC2. Trends in Pharmacological Sciences 41(6):411-425.
[11] Thomanetz V, et al. (2013). mTORC2 and neuroprotection. Development 140(8):1742-1751.
[12] Sarbassov DD. (2005). mTOR signaling and rapamycin. Current Opinion in Cell Biology 17(6):596-603.
[13] Manning BD, Toker A. (2017). Akt/PKB signaling biomarkers. Cell 171(2):251-271.